Cited by 901Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyParaoxonase enzyme and polymorphisms

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

Open access
Ference, Brian A., Yoo, Wonsuk, Alesh, Issa, Mahajan, Nitin, Mirowska, Karolina K., Mewada, Abhishek, Kahn, Joel, Afonso, Luis +2 more·2012·Journal of the American College of Cardiology

Abstract

Objectives The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).Background LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower LDL-C beginning early in life and the risk of CHD has not been reliably quantified.Methods We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it with the clinical benefit associated with the same magnitude of LDL-C reduction during treatment with a statin.Results All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C, with no evidence of heterogeneity of effect (I(2) = 0.0%). In a meta-analysis combining nonoverlapping data from 312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a 54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl) lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that observed during treatment with a statin started later in life (p = 8.43 × 10(-19)).Conclusions Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2012.09.017

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M.
Affiliations
  • Wayne State University (US)
  • University of Tennessee Health Science Center (US)
  • Detroit Medical Center (US)
Corresponding author
Ference, Brian A.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2012-12
Volume
60
Issue
25
Pages
2631-2639
ISSN
0735-1097 (ISSN-L)
OpenAlex
W72392028
Cited by
898
References
44
Citations by year
2026: 69 · 2025: 61 · 2024: 65 · 2023: 80 · 2022: 64 · 2021: 69 · 2020: 81 · 2019: 74 · 2018: 55 · 2017: 48 · 2016: 82 · 2015: 67 · 2014: 41 · 2013: 37 · 2012: 2
FWCI
47.88
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • Medtronic
  • NIH
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
LDL cholesterol, coronary heart disease risk, genetic polymorphism, Mendelian randomization, statin therapy, LDL cholesterol lowering, cardiovascular risk reduction
MeSH terms
Coronary Artery Disease, Follow-Up Studies, Genetic Markers, Humans, Cholesterol, LDL, Polymorphism, Genetic, Risk Factors, Time Factors, Global Health, Incidence, Risk Assessment, Genetic Predisposition to Disease, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review